Arrowhead Announces Improvement in Fibrosis after ARO-AAT Treatment in Patients with Alpha-1 Liver Disease

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Announces Improvement in Fibrosis after ARO-AAT, being co-developed with Takeda, in Patients with the rare genetic Alpha-1 Liver Disease

Click to view original post